Antares Pharma Inc. (ATRS)’s Financial Results Comparing With Penumbra Inc. (NYSE:PEN)

Both Antares Pharma Inc. (NASDAQ:ATRS) and Penumbra Inc. (NYSE:PEN) are each other’s competitor in the Medical Instruments & Supplies industry. Thus the contrast of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Antares Pharma Inc. 74.14M 6.49 5.86M -0.04 0.00
Penumbra Inc. 470.68M 12.31 11.81M 0.27 498.27

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows Antares Pharma Inc. and Penumbra Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Antares Pharma Inc. -7.90% -17.9% -7%
Penumbra Inc. 2.51% 2.8% 2.3%

Volatility & Risk

Antares Pharma Inc. is 5.00% less volatile than Standard & Poor’s 500 due to its 0.95 beta. From a competition point of view, Penumbra Inc. has a 0.72 beta which is 28.00% less volatile compared to Standard & Poor’s 500.

Liquidity

2.3 and 1.9 are the respective Current Ratio and a Quick Ratio of Antares Pharma Inc. Its rival Penumbra Inc.’s Current and Quick Ratios are 6.1 and 4.3 respectively. Penumbra Inc. has a better chance of clearing its pay short and long-term debts than Antares Pharma Inc.

Analyst Ratings

In next table is given Antares Pharma Inc. and Penumbra Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Antares Pharma Inc. 0 0 4 3.00
Penumbra Inc. 0 0 0 0.00

The average price target of Antares Pharma Inc. is $9.04, with potential upside of 205.41%. Competitively the average price target of Penumbra Inc. is $140, which is potential -16.08% downside. Based on the analysts opinion we can conclude, Antares Pharma Inc. is looking more favorable than Penumbra Inc.

Institutional & Insider Ownership

Roughly 41.7% of Antares Pharma Inc. shares are held by institutional investors while 82.2% of Penumbra Inc. are owned by institutional investors. Insiders held 7.3% of Antares Pharma Inc. shares. Comparatively, Penumbra Inc. has 1.9% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Antares Pharma Inc. -3.38% 2.88% -9.21% -21.43% 14.4% 5.15%
Penumbra Inc. -0.16% -2.12% -12.51% -10.1% -10.01% 10.5%

For the past year Antares Pharma Inc.’s stock price has smaller growth than Penumbra Inc.

Summary

Penumbra Inc. beats Antares Pharma Inc. on 11 of the 13 factors.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. In addition, the company is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency. It has strategic alliances and partnership arrangements with Teva Pharmaceutical Industries, Ltd.; AMAG Pharmaceuticals, Inc.; Ferring Pharmaceuticals Inc.; and Ferring B.V. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand. In addition, the company offers neurosurgical aspiration tools for the removal of tissue and fluids under the Apollo System brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the Lantern brand. Further, it provides detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (penumbra occlusion device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as POD Packing Coil, a device for use with RUBY Coil and POD for vessel occlusion. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.